Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer

Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer

Oncology research has changed extensively due to the possibility to categorize each cancer type into smaller subgroups based on histology and particularly on different genetic alterations due to their heterogeneity. The consequences of this heterogeneity are particularly evident in the management of...

Full description

Bibliographic Details
Main Authors:	Antonio Rossi, Sara Pilotto, Luisa Carbognin, Miriam Grazia Ferrara, Lorenzo Belluomini, Gennaro Daniele, Emilio Bria
Format:	Article
Language:	English
Published:	MDPI AG 2021-06-01
Series:	Journal of Molecular Pathology
Subjects:	clinical trials immunotherapy immune checkpoint inhibitors non-small cell lung cancer targeted therapy tyrosine kinase inhibitors
Online Access:	https://www.mdpi.com/2673-5261/2/3/18

Similar Items

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
by: Yuanquan Yang, et al.
Published: (2022-08-01)

Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice
by: Kenta Motomura, et al.
Published: (2023-08-01)

Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
by: Emmy D. G. Fleuren, et al.
Published: (2021-11-01)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
by: Kaito Mimura, et al.
Published: (2022-12-01)

Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
by: Takuto Shimizu, et al.
Published: (2024-02-01)

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-08-01)

Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
by: Vito Longo, et al.
Published: (2019-04-01)

Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
by: Michael A. Harris, et al.
Published: (2022-03-01)

The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma
by: Nicolò Brandi, et al.
Published: (2023-05-01)

Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
by: Federica Cosso, et al.
Published: (2023-02-01)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
by: Fei Yang, et al.
Published: (2022-01-01)

Advances of Targeted Therapy for Hepatocellular Carcinoma
by: Mengke Niu, et al.
Published: (2021-07-01)

Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
by: Mohammad Al-Jundi, et al.
Published: (2020-07-01)

INIBIDORES DAS TIROSINACINASES NA TERAPÊUTICA FARMACOLÓGICA
by: Sara Saraiva, et al.
Published: (2013-09-01)

Inibidores das Tirosinacinases na Terapêutica Farmacológica
by: Sara Saraiva, et al.
Published: (2013-07-01)

The Changing Therapeutic Landscape of Metastatic Renal Cancer
by: Javier C. Angulo, et al.
Published: (2019-08-01)

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
by: Francesca Ragusa, et al.
Published: (2022-05-01)

Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results
by: Alessandro Comandone, et al.
Published: (2021-11-01)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
by: Pan X, et al.
Published: (2023-06-01)

Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
by: Carmelo Laface, et al.
Published: (2022-08-01)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
by: Haohao Lu, et al.
Published: (2023-10-01)

Immunotherapy and Hepatocellular Cancer: Where Are We Now?
by: Marine Valery, et al.
Published: (2022-09-01)

Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
by: Alessia Mennitto, et al.
Published: (2020-03-01)

Emerging treatment modalities for systemic therapy in hepatocellular carcinoma
by: Xin Qing, et al.
Published: (2021-08-01)

The role of sunitinib in the therapy of metastatic renal cell carcinoma
by: I. G. Rusakov, et al.
Published: (2020-07-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
by: Hor-Yue Tan, et al.
Published: (2018-02-01)

Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
by: Daniele Lavacchi, et al.
Published: (2020-06-01)

Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
by: Michela Roberto, et al.
Published: (2021-04-01)

Trial Design for Cancer Immunotherapy: A Methodological Toolkit
by: Everardo D. Saad, et al.
Published: (2023-09-01)

Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials
by: Muhammad Ashar Ali, et al.
Published: (2023-01-01)

FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale
by: Pia Adam, et al.
Published: (2021-08-01)

Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update
by: Shuja Sheikh, et al.
Published: (2021-04-01)

Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas
by: Benoît Pilmis, et al.
Published: (2023-03-01)

Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
by: Estelle Granet-Vaissiere, et al.
Published: (2023-02-01)

Anaplastic Thyroid Cancer: Clinical Picture of the Last Two Decades at a Single Oncology Referral Centre and Novel Therapeutic Options
by: Joana Simões-Pereira, et al.
Published: (2019-08-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
by: Huang JT, et al.
Published: (2022-11-01)

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature
by: Qi Zhu, et al.
Published: (2022-05-01)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
by: Ningning Yan, et al.
Published: (2022-03-01)

Emerging therapies for non-small cell lung cancer
by: Chao Zhang, et al.
Published: (2019-04-01)

Translational research on drug development and biomarker discovery for hepatocellular carcinoma
by: Valerie Chew, et al.
Published: (2024-02-01)